Pharmaceutical - Jazz Pharmaceuticals


Current filters:

Jazz Pharmaceuticals

Popular Filters

Jazz Pharma and Gentium debut Defitelio in Europe


Ireland-headquartered Jazz Pharmaceuticals and its Italian subsidiary Gentium have initiated the European…

AustriaDefitelioEuropeGentiumGermanyJazz PharmaceuticalsMarkets & MarketingPharmaceuticalRare diseases

Jazz Pharma invests in first manufacturing facility in Ireland


Specialty drugmaker Jazz Pharmaceuticals has commenced construction of a manufacturing and development…

DefitelioFinancialJazz PharmaceuticalsNorthern EuropePharmaceuticalProduction

Jazz Pharma in $397 million deal with Aerial for narcolepsy drug ADX-NO5


Ireland-headquartered drugmaker Jazz Pharmaceuticals has inked an agreement with the USA’s Aerial BioPharma…

ADX-NO5Aerial BioPharmaGlobalJazz PharmaceuticalsLicensingNeurologicalPharmaceutical

Italy’s Gentium accepts $1 billion takeover offer from Jazz Pharma


Ireland-headquartered drugmaker Jazz Pharmaceuticals has entered into a definitive agreement to acquire…

defibrotideDefitelioGentiumItalyJazz PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalRare diseases

Jazz Pharma and Concert ink deal on deuterium-modified sodium oxybate


US drugmakers Jazz Pharmaceuticals (Nasdaq: JAZZ) and Concert Pharmaceuticals have entered into an exclusive…

BiotechnologyConcert PharmaceuticalsJazz PharmaceuticalsLicensingNeurologicalPharmaceuticalResearchsodium oxybateZyrem

Landmark US court ruling reverses conviction on off-label drug promotion


The US Court of Appeals for the Second Circuit (based in New York City) on December 3 issued a long-awaited…

Jazz PharmaceuticalsLegalMarkets & MarketingNorth AmericaPharmaceuticalRegulationXyrem

Jazz Pharma sells women's health business to Meda for $95 million


US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced a definitive agreement to sell its women's…

Jazz PharmaceuticalsMedaMergers & AcquisitionsPharmaceuticalWomen's Health

Jazz Pharma to acquire EUSA Pharma for up to $700 million


US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) said last week that it has signed a definitive accord…

EUSA PharmaJazz PharmaceuticalsMergers & AcquisitionsPharmaceutical

Back to top